Galectin Therapeutics (GALT) Competitors $2.51 +0.06 (+2.45%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.56 +0.05 (+1.99%) As of 07/11/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT vs. EOLS, UPB, XNCR, SAGE, KALV, DNTH, RLAY, IOVA, AMLX, and DNAShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Evolus (EOLS), Upstream Bio (UPB), Xencor (XNCR), Sage Therapeutics (SAGE), KalVista Pharmaceuticals (KALV), Dianthus Therapeutics (DNTH), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Its Competitors Evolus Upstream Bio Xencor Sage Therapeutics KalVista Pharmaceuticals Dianthus Therapeutics Relay Therapeutics Iovance Biotherapeutics Amylyx Pharmaceuticals Ginkgo Bioworks Evolus (NASDAQ:EOLS) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings. Do insiders & institutionals have more ownership in EOLS or GALT? 90.7% of Evolus shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 5.9% of Evolus shares are held by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, EOLS or GALT? Evolus has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Which has preferable earnings & valuation, EOLS or GALT? Galectin Therapeutics has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M2.30-$50.42M-$0.89-10.65Galectin TherapeuticsN/AN/A-$47.05M-$0.72-3.49 Does the media refer more to EOLS or GALT? In the previous week, Evolus and Evolus both had 3 articles in the media. Galectin Therapeutics' average media sentiment score of 0.85 beat Evolus' score of 0.52 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EOLS or GALT more profitable? Galectin Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -20.40%. Galectin Therapeutics' return on equity of 0.00% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-20.40% -759.04% -20.14% Galectin Therapeutics N/A N/A -216.05% Do analysts prefer EOLS or GALT? Evolus currently has a consensus target price of $23.75, suggesting a potential upside of 150.53%. Galectin Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 139.04%. Given Evolus' higher probable upside, equities analysts clearly believe Evolus is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryGalectin Therapeutics beats Evolus on 7 of the 13 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.06M$2.50B$5.60B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio-3.499.4227.9620.25Price / SalesN/A723.99429.2099.14Price / CashN/A165.3637.4658.16Price / Book-1.494.608.045.49Net Income-$47.05M$31.26M$3.18B$250.27M7 Day Performance16.47%4.80%3.63%4.75%1 Month Performance87.31%5.42%4.04%7.64%1 Year Performance12.05%-4.36%29.56%16.34% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics2.1115 of 5 stars$2.51+2.4%$6.00+139.0%+6.4%$155.06MN/A-3.499News CoverageEOLSEvolus3.9207 of 5 stars$9.21+0.8%$23.75+157.9%-18.8%$589.31M$266.27M-10.35170UPBUpstream Bio1.9558 of 5 stars$10.98+0.5%$56.50+414.6%N/A$587.97M$2.37M0.0038XNCRXencor4.5178 of 5 stars$7.86-3.4%$28.00+256.2%-54.5%$579.33M$110.49M-2.57280News CoverageSAGESage Therapeutics3.5876 of 5 stars$9.12-0.3%$8.93-2.0%-21.0%$572.98M$41.24M-1.57690Analyst DowngradeHigh Trading VolumeKALVKalVista Pharmaceuticals4.1003 of 5 stars$11.31-0.9%$24.83+119.6%+16.2%$567.26MN/A-3.04100Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionGap DownDNTHDianthus Therapeutics1.5559 of 5 stars$18.63+5.7%$53.00+184.5%-30.8%$566.98M$6.24M-6.4780Positive NewsRLAYRelay Therapeutics2.1616 of 5 stars$3.46+4.8%$17.67+410.6%-53.6%$565.77M$10.01M-1.55330News CoverageInsider TradeIOVAIovance Biotherapeutics4.6855 of 5 stars$1.72+1.8%$12.22+610.6%-77.8%$564.35M$164.07M-1.39500Trending NewsAMLXAmylyx Pharmaceuticals3.4212 of 5 stars$6.41+1.3%$11.00+71.6%+236.8%$564.26M$87.37M-2.06200Analyst UpgradeDNAGinkgo Bioworks0.7845 of 5 stars$11.29+19.3%$5.77-48.9%N/A$553.71M$227.04M-1.23640News CoverageGap Down Related Companies and Tools Related Companies EOLS Alternatives UPB Alternatives XNCR Alternatives SAGE Alternatives KALV Alternatives DNTH Alternatives RLAY Alternatives IOVA Alternatives AMLX Alternatives DNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GALT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GALT Stock Alerts